Trial Profile

A Biomarker-Guided Trial to Evaluate ALRN-6924 in Combination with IBRANCE (Palbociclib) in MDM2-Amplified Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
Indications Glioblastoma; Liposarcoma; Osteosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Aileron Therapeutics

Most Recent Events

21 Feb 2023 According to an Aileron Therapeutics media release, based on the data from phase 1b breast cancer trial, company decided to terminate the further development of ALRN-6924.
21 Feb 2023 Status changed from recruiting to discontinued, according to an Aileron Therapeutics media release.
09 Aug 2019 Planned number of patients changed from 25 to 35 as per the Aileron Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com